Key Points
- Chairman Fred Lampropoulos sold 10,000 shares on Nov. 25 at an average price of $88.04 for $880,400, trimming his position by 0.97% to 1,019,955 shares valued at about $89.8 million (SEC filing).
- Company results and outlook: Merit beat Q3 estimates with $0.92 EPS (vs. $0.82) and $384.16M revenue (+13% YoY), set FY2025 guidance of $3.66–$3.79 EPS, and carries a consensus "Moderate Buy" analyst rating with an average target of $104.50.
Merit Medical Systems, Inc. (NASDAQ:MMSI - Get Free Report) Chairman Fred Lampropoulos sold 10,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $88.04, for a total transaction of $880,400.00. Following the completion of the sale, the chairman directly owned 1,019,955 shares of the company's stock, valued at $89,796,838.20. This trade represents a 0.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Merit Medical Systems Trading Down 0.2%
NASDAQ MMSI opened at $87.41 on Thursday. The stock has a market cap of $5.18 billion, a P/E ratio of 44.37, a PEG ratio of 2.62 and a beta of 0.64. The company's fifty day simple moving average is $84.08 and its 200-day simple moving average is $88.36. The company has a current ratio of 4.09, a quick ratio of 2.66 and a debt-to-equity ratio of 0.49. Merit Medical Systems, Inc. has a 52 week low of $78.12 and a 52 week high of $111.45.
Merit Medical Systems (NASDAQ:MMSI - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical instruments supplier reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.82 by $0.10. Merit Medical Systems had a net margin of 8.31% and a return on equity of 15.07%. The business had revenue of $384.16 million during the quarter, compared to analyst estimates of $371.69 million. During the same period last year, the business earned $0.86 EPS. The business's revenue was up 13.0% on a year-over-year basis. Merit Medical Systems has set its FY 2025 guidance at 3.660-3.790 EPS. Equities research analysts predict that Merit Medical Systems, Inc. will post 3.37 EPS for the current fiscal year.
Analyst Ratings Changes
Several analysts have recently weighed in on the company. Weiss Ratings restated a "hold (c)" rating on shares of Merit Medical Systems in a research note on Monday. Wells Fargo & Company reduced their price target on Merit Medical Systems from $103.00 to $95.00 and set an "overweight" rating for the company in a report on Friday, November 14th. Robert W. Baird set a $103.00 price objective on Merit Medical Systems in a research note on Friday, October 31st. Piper Sandler reaffirmed an "overweight" rating and issued a $109.00 target price (up from $105.00) on shares of Merit Medical Systems in a research report on Friday, October 31st. Finally, Raymond James Financial reduced their target price on Merit Medical Systems from $108.00 to $102.00 and set an "outperform" rating for the company in a research note on Thursday, July 31st. Eight investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $104.50.
Read Our Latest Report on Merit Medical Systems
Institutional Trading of Merit Medical Systems
Institutional investors have recently added to or reduced their stakes in the business. Evergreen Capital Management LLC grew its stake in Merit Medical Systems by 2.4% during the 1st quarter. Evergreen Capital Management LLC now owns 4,616 shares of the medical instruments supplier's stock worth $488,000 after buying an additional 108 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Merit Medical Systems by 2.2% during the second quarter. Ameritas Investment Partners Inc. now owns 5,973 shares of the medical instruments supplier's stock valued at $558,000 after acquiring an additional 131 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Merit Medical Systems by 55.6% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 375 shares of the medical instruments supplier's stock valued at $35,000 after acquiring an additional 134 shares during the period. Norden Group LLC grew its position in shares of Merit Medical Systems by 5.7% during the third quarter. Norden Group LLC now owns 2,536 shares of the medical instruments supplier's stock worth $211,000 after acquiring an additional 137 shares during the last quarter. Finally, US Bancorp DE increased its holdings in shares of Merit Medical Systems by 3.8% in the 1st quarter. US Bancorp DE now owns 3,936 shares of the medical instruments supplier's stock worth $416,000 after acquiring an additional 145 shares during the period. Institutional investors own 99.66% of the company's stock.
About Merit Medical Systems
(
Get Free Report)
Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
